



PRESS RELEASE

CEGEDIM S.A. COMPLETES ACQUISITION OF DENDRITE INTERNATIONAL, INC.

Paris, France, May 9, 2007 - CEGEDIM S.A. (Euronext: CGM) today announced the completion of its acquisition of Dendrite International, Inc. (NASDAQ: DRTE), in accordance with the terms of an Agreement and Plan of Merger announced on March 2, 2007. Dendrite shareholders approved the acquisition on May 4, 2007, and the companies have today met all regulatory approvals required for closing.

The combined company will create a major player in diversified sales, marketing and compliance solutions to the global life sciences and pharmaceutical industry. With a unique suite of integrated, value-added products, the new company can address the global needs of its customers, especially by merging CEGEDIM's European strength with Dendrite's US and Asia-Pacific key position.

Under the terms of the Agreement and Plan of Merger, CEGEDIM will pay \$16.00 per outstanding share in cash for each share of Dendrite International common stock outstanding, that is a total purchase price of \$751 million. CEGEDIM has financed this acquisition by a combination of cash on hand and a fully committed bank facility. As of May 9, 2007 Dendrite will be wholly owned and will start contributing to Cegedim's consolidated results. On a pro forma full year basis, the combined entity is expected to have estimated revenues of \$1.1 billion.

"We are pleased to close this transaction and to accelerate the integration of our two companies" says Jean-Claude Labrune, Founder, Chairman and Chief Executive Officer of CEGEDIM. "Dendrite truly has a very talented team, and together we will extend our geographical presence while continuing to invest in the development of innovative technologies. Our combined organization has enhanced product offerings and is focused on providing the highest level of service to our customers around the globe."

Dendrite's shares will cease to trade on the NASDAQ at the close of business May 9, 2007.

About CEGEDIM:

CEGEDIM develops exclusive databases and high value added software solutions. Its expertise falls into two divisions. The "Healthcare and strategic data" division comprises services specifically designed for pharmaceutical companies, healthcare professionals and health insurance providers. The "Technologies and services" division covers a variety of sectors.

Established as the European leader in its historic core business, CEGEDIM provides the world's largest pharmaceutical companies with vital support for successful CRM (Customer Relationship Management) and helps measure sales & marketing effectiveness. CEGEDIM's CRM tools, backed by the Group's powerful strategic databases, also provide its clients with a clearer picture of their markets and targets, optimizing both strategies and return on investment. Founded in 1969, and the only European company operating globally in this market, CEGEDIM employs around 5,000 people and generated turnover of €541 million in 2006 in 75 countries. To learn more, please see our website: www.cegedim.com.

Listed on Eurolist by Euronext Paris, compartment B – ISIN FR0000053506 – Reuters CGDM.PA – Bloomberg CGM

About Dendrite:

Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, marketing, clinical and compliance solutions for the global pharmaceutical industry. The Company's clients are located in more than 50 countries and include the world's top 20 pharmaceutical companies. For more information, please visit www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

Media inquiries

Investor relations

CEGEDIM

Aude Balleydier
Media Relations

Tel: + 33 (0)1 49 09 68 81

aude.balleydier@cegedim.fr

VP COMMUNICATION

Coralie Voigt
Press Officer

Tel: + 33 (0)1 40 22 04 01

cvoigt@vp-communication.com

CEGEDIM

Sandrine Debroise
Chief Financial Officer

Tel: + 33 (0)1 49 09 22 00

investor.relations@cegedim.fr